NEW PHOTOCHROMIC COMPOUNDS AND INTERMEDIATE COMPOUNDS FOR PRODUCTION THEREOF

Abstract

The invention covers new bicyclic bridged [1,3]oksazepine derivatives of the general formula (I) and (II):

##STR00001##

which exhibit enhanced photochromic properties as compared with known spiropyrans and can be used as molecular photoswitches. The method of production of new compounds and intermediates for preparation thereof are disclosed.

Claims

1. Compounds of the general formula (I) or (II) ##STR00018## wherein R.sup.1 and R.sup.2 each independently is C.sub.1-C.sub.3-alkyl or R.sup.1 and R.sup.2 together are forming (CH.sub.2).sub.4—; —(CH.sub.2).sub.5—; R.sup.3 is C.sub.1-C.sub.6 alkyl, benzyl, phenyl, allyl.

2. The compounds of the general formula (I) or (II) according to claim 1, wherein R.sup.1 is methyl, R.sup.2 is methyl, and R.sup.3 is ethyl or benzyl.

3. The compound according to claim 1, which is (5aR*,12R*,13S*.sup.□)—N-ethyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepine-12-carboxamide (6a).

4. The compound according to claim 1, which is (5aR*,12S*,13S*)—N-ethyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepin-12-carboxamide (7).

5. The compound according to claim 1, which is (5aR*,12S*,13S*)—(N-benzyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepin-12-carboxamide (6b).

6. The compound according to claim 1, which is exhibiting photochromic properties with characteristic relaxation time of less than 5 ns.

7. A method of using the compounds according to claim 1 comprising using said compounds as molecular photoswitches.

8. Compounds of the general formula (5), ##STR00019## wherein R.sup.3 is ethyl or benzyl.

9. Compounds of the general formula (4), ##STR00020## wherein R.sup.3 is ethyl or benzyl.

10. 7-Methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one of the formula (3) ##STR00021##

11. 1-Carbamoylmethyl-5-methoxy-2,3,3-trimethyl[3H]indolium chloride of the formula (2) ##STR00022##

12. The compound according to claim 2, which is (5aR*,12R*,13S*.sup.□)—N-ethyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepine-12-carboxamide (6a).

13. The compound according to claim 2, which is (5aR*,12S*,13S*)—N-ethyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepin-12-carboxamide (7).

14. The compound according to claim 2, which is (5aR*,12S*,13S*)—(N-benzyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepin-12-carboxamide (6b).

15. The compound according to claim 2, which is exhibiting photochromic properties with characteristic relaxation time of less than 5 ns.

16. The compound according to claim 3, which is exhibiting photochromic properties with characteristic relaxation time of less than 5 ns.

17. The compound according to claim 12, which is exhibiting photochromic properties with characteristic relaxation time of less than 5 ns.

18. The compound according to claim 4, which is exhibiting photochromic properties with characteristic relaxation time of less than 5 ns.

19. The compound according to claim 13, which is exhibiting photochromic properties with characteristic relaxation time of less than 5 ns.

20. The compound according to claim 5, which is exhibiting photochromic properties with characteristic relaxation time of less than 5 ns.

Description

SHORT DESCRIPTION OF DRAWINGS

[0012] The invention is illustrated by the drawings, wherein:

[0013] FIG. 1 shows kinetic spectra of compound 6a in acetonitrile after addition of NaOH (1 mMol NaOH);

[0014] FIG. 2 shows kinetic spectra of compound 6b in acetonitrile after addition of NaOH (1 mMol NaOH);

DISCLOSURE OF THE INVENTION

[0015] The goal of present invention is to get new photochromic compounds, that act by openind and closing of 3,4-dihydropyrane ring in methanobenz[f][1,3]oxazepino[3,2-a]indoles, which rate of opening/closing be higher than of known photochroms, and be active in both neutral and alkaline mediums.

[0016] To achieve this goal the compounds of general formulae (I) and (II) are proposed

##STR00005##

[0017] wherein

[0018] R.sup.1 and R.sup.2 each independently are methyl, ethyl or are part of spirocycle: —(CH.sub.2).sub.4; —(CH.sub.2).sub.5—;

[0019] R.sup.3 is C.sub.1-C.sub.6-alkyl, ω-functionalized alkyl, benzyl, phenyl, allyl.

[0020] Here ω-functionalized alkyl is having polymerizable groups (vinyl, acrylate, epoxy) or tiol groups, capable of connecting to various substrates.

[0021] More specifically, the present invention covers compounds of the general formula (I) or (II) wherein R.sup.1 and R.sup.2 are methyls and R.sup.3 is ethyl or benzyl.

[0022] Preferred target compounds of present invention are: [0023] (5aR*,12R,13S)—N-Ethyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepine-12-carboxamide (6a); [0024] (5aR,12S,13S*)—N-Ethyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepine-12-carboxamide (7); [0025] (5aR*,12R*, 13S)—N-Benzyl-6,6,8-trimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepine-12-carboxamide (6b).

[0026] The target compounds of the present invention are characterized by photochromic properties. They can be used as photochromic switches.

[0027] Another object of the invention are compounds of general formula (5),

##STR00006##

[0028] wherein R.sup.3 is ethyl or benzyl, and which compounds are intermediates for obtaining photochromic compounds of present invention.

[0029] Yet another object of present invention are compounds of general formula (4), which are used in synthesis of compounds (5):

##STR00007##

[0030] wherein R.sup.3 is ethyl or benzyl.

[0031] Another one object of present invention is compound of formula (3), which is used in synthesis of compound (4):

##STR00008##

[0032] One more object of present invention is 3H-indolium salt of formula (2), which is used in synthesis of compound of formula (3):

##STR00009##

DETAILED DESCRIPTION OF THE INVENTION

[0033] New class of photochromic compounds is developed, comprising derivatives of general formula (I) and (II) cis- and trans-methanobenz[f][1,3]oxazepino[3,2-a]indole derivatives

##STR00010##

[0034] These derivatives have skeleton of 1′,3,3′,4-tetrahydrospiro[chromen-2,2′-indole]formed from indole (A) and chromane(B) heterocyclic systems, similarly to recently published fotochromic compounds, 1′,3′,3′-trimethyl-6-nitro-1′,3,3′,4-tetrahydrospiro[chromen-2,2′-indoles] III and IV.

[0035] However, compounds of present invention are bearing an additional C—C bond (shown above in bold), which reduces conformational lability of pyrane ring.

##STR00011##

[0036] The structure of compounds of present invention was found to be pecular in that under the action of ultraviolet radiation on compound type I, breaking of C—O bond in 3,4-dihydro[2H]pyrane ring occurrs, generating coloured zwitterion V, possessing coloured 4-nitrophenolate fragment. This fragment is connected by only one bond, being able to turn about it. Meanwhile, when known high speed photochroms A are triggered by UV irradiation, zwitterionic compound B generates, in which 4-nitrophenolate moiety is connected with indolium moiety through three single bonds around which rotation is possible. The reduction of degree of freedom due to possible rotation around single C—C bonds in the structure V (1 bond), comparing with structure B (3 bonds), is advantageous in that dihydropyrane ring restors quicker than 5 ns, and compound V returns to the initial structure I.

[0037] As mentioned above, the invention includes novel intermediates, necessary to obtain the target compounds.

[0038] To the knowledge of the authors, intermediates (2) (3) (4) (5) are not described, though they may be prepared by known synthesis methods. Intermediates of general formula (5) were obtained by condensing the compounds of the general formula (4), e.g. with 2-hydroxy-5-nitrobenzaldehyde. Compounds of the general formula (4) were prepared by alkylation of 7-methoxy-9,9,9a-trimethyl-9H-imidazo[1,2-a]indol-2-ona with iodoethane or benzylchloride. Compound of formula (3) was obtained by cyclization of 3H-indolium salt, and the latter salt of formula (2) was obtained by alkylation of 2,3,3a-trimethyl-5-methoxy-3H-indole by 2-chloroacetamide. For skilled specialists in organic synthesis it is understandable, how to prepare other compounds of present invention.

[0039] It was found by the treatments that, that when solutions of compounds proposed in the present invention were irradiated with monochromatic ultraviolet light (for example, Nd:YAG laser (EKSPLA NL30); third harmonic; wavelength 355 nm; pulse duration—5 ns; pulse energy 3 mJ) heterolytic breaking of bond connecting chiral center (marked by asterix) with oxygen atom occurrs yielding formation of cwitterionic compound, comprising the conformationally constrained chain of two carbon atoms connecting fragments of 3H-indolium cation and coloured 4-nitrophenolate anion. After switching irradiation off the coloured form of compound thermally returns to the initial colourless state, after connection of oxygen atom of phenolate anion to α-carbon atom of indole ring system. Compounds of the present invention methanobenz[f][1,3]oxazepino[3,2-a]indoles are characterized by higher total speed of cycle closing/opening, besides they operate in oxygen environment as well. cis-Methanobenz[f][1,3]oxazepino[3,2-a]indoles are less sensitive to pH of environment, especially for alkaline medium, while 6-nitro-1′,3,3′,4-tetrahydrospiro[chromen-2,2′-indoles] are extremely sensitive to the bases. Compounds described in present patent application were synthesized by recyclization reaction of corresponding indolino spiropyrane, when treated with potassium hydroxyde in ethanol under reflux.

[0040] Said methanobenz[f][1,3]oxazepino[3,2-a]indoles are obtainable according to general scheme below:

##STR00012##

MODES FOR CARRYING OUT THE INVENTION

[0041] Information on examples of real embodiments is provided below, disclosing the modes of preparation compounds of present invention and properties thereof. This information is provided for the illustrative purpose and is not limiting the scope of present invention.

Example 1

5-Methoxy-2,3,3-trimethyl-3H-indolium chloride (initial compound)

[0042] 5-Methoxy-2,3,3-trimethyl-3H-indole 12 g (0,063 mol) was dissolved in toluene (20 ml), condenser was attached to the flask and acethyl chloride 9 ml (p=1.104 g/Ml, 9,94 g) was added dropwise. After cooling the mixture to ambient temperature, the mixture was stored at 5° C. for 12 h. Formed crystals were filtered, washed with acetone and cold ether. Yield is 6.6 g of indolium chloride (46.12%) as yellowish crystals. M.p. 201-203° C. .sup.1H NMR (400 MHz, DMSO-D.sub.6): δ 1.45 (s, 6H, 2×CH.sub.3), 2.62 (s, 3H, 2-CH.sub.3), 3.82 (s, 3H, 5-OCH.sub.3), 7.02 (dd, J=8.8 Hz, J=2.4 Hz, 1H, 6-H), 7.37 (d, J=2.4 Hz, 1H, 4-H), 7.54 (d, J=8.4 Hz, 1H, 7-H). .sup.13C BMR (100 MHz, DMSO-D.sub.6): δ 14.3, 22.0 (2×C), 53.8, 55.9, 109.4, 113.9, 117.2, 134.9, 145.3, 159.7, 193.0. IR (KBr), ν (cm.sup.−1): 3134 (N—H), 3021, 2973, 1623, 1479, 1404, 1289, 1022, 797.

Example 2

1-Carbamoylmethyl-5-methoxy-2,3,3-trimethyl [3H]indolium chloride (Intermediate Compound 2)

[0043] 5-Methoxy-2,3,3-trimethyl-3H-indolium chloride (6 g, 0.026 mol) obtained according to Example 1 was dissolved in minimal amount of water, neutralized with sodium carbonate and extracted with diethyl ether (2×30 ml). Combined extract was dried over anhydrous sodium sulfate and solvent was removed on rotavapor. To the obtained residue (4.8 g, 0,025 mol) α-chloroacetamide (2.6 g, 0.027 mol) was added and the mixture was heated at 140° C. for 2 h in o-xylene (7 ml) with condenser. After cooling the formed crystals were filtered and washed with cold ether. After recrystallization from ethanol 5 g of product was obtained, yield 69.7% of dark brown crystals, m.p. 240-242° C. .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ 1.54 (s, 6H, 2×CH.sub.3), 2.73 (s, 3H, CH.sub.3), 3.85 (s, 3H, O—CH.sub.3), 5.36 (s, 2H, CH.sub.2CO), 7.14 (dd, J=8.8 Hz, J=2.4 Hz, 1H, 6-H), 7.51 (d, J=2.4 Hz, 1H, 4-H), 7.79-7.81 (m, 2H, 7-H, ½NH.sub.2), 8.51 (pl.s, 1H, % NH.sub.2). .sup.13C BMR (100 MMHz, DMSO-D.sub.6): δ 14.4, 22.6 (2×C), 50.1, 54.5, 56.6, 109.9, 114.9, 116.3, 135.2, 143.9, 161.1, 165.1, 196.4. IR (KBr), ν (cm.sup.−1): 3290 (N—H), 3097, 2977, 1689 (C═O), 1298, 1030, 833.

Example 3

7-Methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one (Intermediate Compound 3)

[0044] 1-Carbamoylmethyl-5-methoxy-2,3,3-trimethyl-3H-indolium chloride (5 g, 0,018 mol), that was synthesized according method of example 2, was dissolved in minimal amount of water, neutralized with sodium carbonate and extracted with diethyl ether (2×25 ml). Etheral extracts were combined, dried over anhydrous sodium sulphate and solvent was evaporated on rotavapor. To the obtained neutralized mixture (5 g, 0.02 mmol) ethanol (20 ml) and glacial acetic acid (9.2 ml) were added and the mixture was heated at 100° C. for 1 h. After cooling the mixture it was poured into water (50 ml) and neutalized with Na.sub.2CO.sub.3, till white crystals start forming. The substance was filtered, washed with water and re-crystallized from ethanol. Yield of product 2.5 g (50%) as of white crystals, m.p. 209-211° C. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 1.17 (s, 3H, CH.sub.3), 1.36 (s, 3H, CH.sub.3), 1.50 (s, 3H, CH.sub.3), 3.76 (s, 3H, O—CH.sub.3), 3.77 (AB-q, J=16.4 Hz, 2H, CH.sub.2), 6.62 (d, J=2.8 Hz, 1H, 4-H), 6.64 (d, J=8.8 Hz, 1H, 7-H), 6.70 (dd, J=8.8 Hz, J=2.4 Hz, 1H, 6-H), 7.86 (pl. s, 1H, NH). .sup.13C BMR (100 MHz, CDCl.sub.3): δ 21.2, 22.3, 27.5, 47.0, 55.8, 55.9, 92.0, 109.1, 112.8, 113.3, 140.2, 144.3, 155.9, 174.9 (C═O). IR (KBr, cm.sup.−1): 3333 (N—H), 3056, 2975, 1700 (C═O). MS m/z (%): 247 (M+H+, 100).

Example 4

1-Ethyl-7-methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one (Intermediate Compound 4a)

[0045] 7-Methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one 2,5 g (0.01 mol), that was synthesized according to method described for example 3, was dissolved in dimethylformamide (25 ml) and to the solution freshly powdered KOH (0,85 g) was added. After dissolution of alkali, iodoethane (2.45 ml) was added dropwise and stirring was continued for 3 h. The mixture was poured into water and extracted with ether (3×20 ml). Etheral extracts were combined, washed with 5% solution of HCl. Neutralized with Na.sub.2CO.sub.3 solution, dried over anhydrous sodium sulphate and solvent was evaporated on rotavapor. Yield of product 2.3 g (82.7%) as yellowish resinous substance. 1H NMR (400 MHz, CDCl.sub.3): δ 1.04 (s, 3H, CH.sub.3), 1.29 (t, J=7.2 Hz, 3H, CH.sub.2CH.sub.3), 1.40 (s, 3H, CH.sub.3), 1.47 (s, 3H, CH.sub.3), 2.98-3.07 (m, 1H, ½CH.sub.2CH.sub.3), 3.63-3.72 (m, 1H, % CH.sub.2CH.sub.3), 3.76 (s, 3H, OCH.sub.3), 3.83 (AB-q, J=15.2 Hz, 2H, CO—CH.sub.2), 6.59 (d, J=2.8 Hz, 1H, 4-H), 6.70-6.71 (m, 2H, Ar—H). .sup.13C NMR (100 MHz, CDCl.sub.3): δ 14.33, 23.07, 24.11, 27.02, 29.19, 37.23, 50.06, 55.84, 92.69, 108.99, 113.01, 115.36, 142.23, 142.99, 156.05, 171.22 (C═O). IR (KBr), ν (cm.sup.−1): 3029, 2984, 1703 (C═O), 1491, 1273, 1014, 816.

Example 5

1-Benzyl-7-methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one (Intermediate Compound 4b)

[0046] 7-Methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one 2,0 g (0,008 mol), that was synthesized according to method described for example 3, was dissolved in dimethylformamide (18 mL), and to the solution 0,7 g (0.12 mol) freshly grounded KOH was added. After dissolution of alkali 3.08 benzyl chloride was added dropwise 2.8 mL (0,024 mol, p=1.100 g/Ml, 3.08 g) and stirring continued for 3 hrs at room temperature. The mixture was poured into water and extracted with ether (3×20 mL). Combined extract was washed with 5% HCl solution and neutralized with Na.sub.2CO.sub.3 solution. Solvent was dried over anhydrous sodium sulphate and evaporated with rotavapor. Obtained resin was purified by column chromatography (eluent: hexane/acetone 3:1). Yield of product 1.4 g (51.8%) as slightly orange crystals, m.p. 122-123° C. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 1.01 (s, 3H, 9a-CH.sub.3, 1.25 (s, 3H, 9-CH.sub.3), 1.37 (s, 3H, 9-CH.sub.3), 3.73 (AB-d, J=15.2 Hz, 1H, ½CH.sub.2CO), 3.73 (s, 3H, 7-OCH.sub.3), 4.14 (dd, J=15.5 Hz, J=5.8 Hz, 2H, CH.sub.2-Ph), 4.95 (AB-d, J=15.6 Hz, 1H, ½CH.sub.2CO), 6.55 (d, J=2.5 Hz, 1H, 8-H), 6.69 (dd, J=8.4 Hz, J=2.5 Hz, 1H, 6-H), 6.74 (d, J=8.4 Hz, 1H, 5-H), 7.21-7.28 (m, 5H, Ar—H). .sup.13C NMR (100 MHz, CDCl.sub.3): δ 23.3, 23.9, 28.7, 45.4, 50.1, 55.7, 55.8, 93.1, 108.9, 113.0, 115.6, 127.5, 127.6 (2×C), 128.7 (2×C), 137.7, 142.1, 143.2, 156.2, 172.1 (C═O). IR (KBr), ν (cm 1): 3023, 2969, 1706 (C═O), 1493, 1278, 1027, 730.

Example 6

N-Ethyl-2-(5′-methoxy-3′,3′-dimethyl-6-nitrospiro[chromen-2,2′-indolo]-1′(3′H)-yl)acetamide (Intermediate Compound 5a)

[0047] 1-Ethyl-7-methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one 2,5 g (0.009 mol), that was synthesized according method described for example 4, and 2-hydroxy-5-nitrobenzaldehyde 1.52 g (0.009 mol) were added to glacial acetic acid (20 mL) and heated at 100° C. for 3 hrs. After reaction completion the mixture was poured into 5% sodium acetate solution (250 mL) and extracted with ethyl acetate (2×30 ml). Combined extract was dried over anhydrous sodium sulfate and solvent was removed on rotavapor. Obtained resin was purified by column chromatography (eluent: hexane/acetone 3:1). Yield of product 1.3 g (33.8%) as violet amorphous substance. M.p. 95-96° C. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 1.09 (t, J=7.2 Hz, 3H, CH.sub.2CH.sub.3), 1.26 (s, 3H, 3′-CH.sub.3), 1.3 (s, 3H, 3′-CH.sub.3), 3.25-3.34 (m, 2H, CH.sub.2CH.sub.3), 3.59 (AB-d, J=17.6 Hz, 1H, ½CH.sub.2CO), 3.80 (s, 3H, 5′-OCH.sub.3), 3.87 (AB-d, J=17.6 Hz, 1H, ½CH.sub.2CO), 5.83 (d, J=10.4 Hz, 1H, CH═CH), 6.43 (d, J=8.4 Hz, 1H, 7′-H), 6.49 (t, J=5.2 Hz, 1H, NH), 6.72 (dd, J=8.4 Hz, J=2.8 Hz, 1H, 6′-H), 6.75-6.78 (m, 2H, 4-H, 4′-H), 6.94 (d, J=10.4 Hz, 1H, CH═CH), 8.00 (d, J=2.8 Hz, 1H, 7-H), 8.03 (dd, J=8.8 Hz, J=2.8 Hz, 1H, 5-H). .sup.13C NMR (100 MHz, CDCl.sub.3): δ 15.0, 20.1, 26.1, 27.0, 34.3, 48.8, 52.9, 56.0, 106.6 (spiro-C), 108.3, 110.0, 111.7, 115.6, 118.3, 120.4, 123.1, 126.3, 129.4, 137.8, 140.0, 141.5, 155.4, 158.8, 169.3 (C═O). IR (KBr), ν (cm.sup.−1): 3403 (N—H), 3065, 2966, 1666 (C═O), 1520, 1481, 1337, 1273, 1089, 951.

Example 7

N-Benzyl-2-(5′-methoxy-3′,3′-dimethyl-6-nitrospiro[chromen-2,2′-indolo]-1′(3′H)-yl)acetamide (Intermediate Compound 5b)

[0048] 1-Benzyl-7-methoxy-9,9,9a-trimethyl-9,9a-dihydro-1H-imidazo[1,2-a]indol-2(3H)-one 1.0 g (0.003 mol), that was synthesized according method described for example 5, and 2-hydroxy-5-nitrobenzaldehyde (0.5 g, 0.003 mol) were added to glacial acetic acid (10 mL) and heated at 100° C. for 3 hrs. After reaction completion the mixture was poured into 5% sodium acetate solution (100 mL) and extracted with ethyl acetate (2×30 ml). Combined extract was dried over anhydrous sodium sulfate and solvent was removed on rotavapor. Obtained resin was purified by column chromatography (eluent: hexane/acetone 3:1). Yield of product 0.41 g (28.7%) as violet amorphous substance. M.p. 84-85° C. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 1.18 (s, 3H, 3′-CH.sub.3), 1.27 (s, 3H, 3′-CH.sub.3), 3.71 (AB-d, J=17.6 Hz, 1H, ½CH.sub.2CO), 3.80 (s, 3H, 5′-OCH.sub.3), 3.91, (AB-d, J=17.6 Hz, 1H, ½CH.sub.2CO), 4.45 (d, J=5.6 Hz, 2H, CH.sub.2-Ph), 5.76 (d, J=10.2 Hz, 1H, CH═CH), 6.45 (d, J=8.0 Hz, 1H, 4-H), 6.60 (d, J=8.4 Hz, 1H, 6′-H), 6.71 (dd, J=8.4 Hz, J=2.4 Hz, 1H, 7′-H), 6.74 (d, J=2.4 Hz, 1H, 4′-H), 6.83 (t, J=5.8 Hz, 1H, NH), 6.92 (d, J=10.2 Hz, 1H, CH═CH), 7.14-7.17 (m, 2H, Ar—H), 7.27-7.29 (m, 3H, Ar—H), 7.96-7.80 (m, 2H, 5-H, 7-H). .sup.13C NMR (100 MHz, CDCl.sub.3): δ 20.14, 26.10, 43.43, 48.75, 52.97, 56.06, 106.65 (spiro-C), 108.23, 110.06, 111.79, 115.61, 118.29, 120.51, 123.03, 126.31, 127.57 (2×C), 127.72, 128.87 (2×C), 129.41, 137.66, 138.0, 139.84, 141.58, 155.38, 158.66, 169.49 (C═O). IR (KBr), ν (cm.sup.−1): 3395 (N—H), 3030, 2930, 1671 (C═O), 1519, 1494, 1481, 1337, 1272, 1089, 951.

Example 8

(5aR*,12S*,13S*)- and (5aR*,12R*,13S*)—N-Ethyl-8-methoxy-6,6-dimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepino-12-carboxamides (Target Compounds 6a, 7)

[0049] Spirocompound 5a (1 g, 0.002 mol), that was synthesized according to method described in example 6, was dissolved in ethanol (30 mL), fine grounded potassium hydroxyde (0.34 g, 0.006 mol) was added and the mixture was refluxed for 2 hrs. After reaction completion the most of solvent was removed on rotavapor, and to the residue water was added dropwise till solution became turbid. The mixture was hold at 5° C. for 10 hrs. Formed crystals were filtered, washed with small amount of cold ether, and recrystallized from ethanol. Filtrate was extracted with ethyl acetate (2×30 ml), combined extract was dried over anhydrous sodium sulfate and solvent was removed on rotavapor. Residue was purified by column chromatography (eluent: hexane/acetone 5:1). Obtained product was recrystallized from ethanol.

[0050] Cis-Isomer (6a)

[0051] Yield 10.4%, yellow crystals, m.p. 241-242° C. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 0.61 (t, J=7.2 Hz, 3H, CH.sub.2CH.sub.3), 1.48 (s, 3H, 6-CH.sub.3), 1.50 (s, 3H, 6-CH.sub.3), 2.16 (d, J=11.6 Hz, 1H, 14-Ha), 2.20 (dd, J=11.6 Hz, J=3.6 Hz, 1H, 14-H.sub.b), 2.81-2.91 (m, 1H, ½CH.sub.2CH.sub.3), 3.12-3.23 (m, 1H, ½CH.sub.2CH.sub.3), 3.78 (s, 3H, 8-OCH.sub.3), 3.80 (t, J=3.6 Hz, 13-H), 3.88 (d, J=4.8 Hz, 1H, 12-H), 6.43 (d, J=9.2 Hz, 1H, Ar—H), 6.66-6.69 (m, 2H, Ar—H), 6.89-6.92 (m, 2H, Ar—H, NH), 7.98 (d, J=2.8 Hz, 1H, 1-H), 8.07 (dd, J=9.2 Hz, J=2.8 Hz, 1H, 3-H). .sup.13C NMR (100 MHz, CDCl.sub.3): δ 14.7, 23.11, 26.6, 32.9, 33.7, 42.4, 45.5, 56.0, 78.2, 109.6, 111.1, 111.5, 113.1, 116.3, 124.7, 125.1, 125.9, 139.8, 141.4, 142.4, 156.0, 158.4, 169.5 (C═O). IR (KBr), ν (cm.sup.−1): 3288 (N—H), 3071, 2982, 1652 (C═O), 1513, 1344, 1269, 1090, 816.

[0052] Trans-Isomer (7)

[0053] Yield 2.5%, yellowish crystals, m.p. 184-185° C. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 1.09 (t, J=7.2 Hz, 3H, CH.sub.2CH.sub.3), 1.37 (s, 3H, 6-CH.sub.3), 1.60 (s, 3H, 6-CH.sub.3), 2.05 (d, J=11.6 Hz, 1H, 14-Ha), 2.69 (dd, J=11.6 Hz, J=4.0 Hz, 1H, 14-H.sub.b), 3.24-3.35 (m, 2H, CH.sub.2CH.sub.3), 3.75 (s, 3H, 8-OCH.sub.3), 3.77 (d, J=4.0 Hz, 1H, 13-H), 4.31 (s, 1H, 12-H), 5.97 (t, J=5.2 Hz, 1H, NH), 6.25 (d, J=8.4 Hz, 1H, 10-H), 6.59 (dd, J=8.4 Hz, J=2.4 Hz, 1H, 9-H), 6.75 (d, J=2.4 Hz, 1H, 7-H), 6.79 (d, J=9.2 Hz, 1H, 4-H), 8.03 (dd, J=8.8 Hz, J=2.8 Hz, 1H, 3-H), 8.16 (d, J=2.8 Hz, 1H, 1-H). IR (KBr), ν (cm.sup.−1): 3298 (N—H), 3082, 2970, 1650 (C═O), 1510, 1496, 1338, 1268, 1086, 917.

Example 9

(5aR*,12S*,13S*)—N-Benzyl-8-methoxy-6,6-dimethyl-2-nitro-12,13-dihydro-6H-5a,13-methanoindolo[2,1-b][1,3]benzoxazepino-12-carboxamide (Target Compound 6b)

[0054] Spirocompound 5b 0.385 g (0.8 mmol), that was synthesized according to method described in example 7 was dissolved in ethanol (10 mL), fine ground potassium hydroxide (0.13 g, 2.4 mmol) was added and the mixture was refluxed for 2 hrs. After reaction completion the most of solvent was removed on rotavapor and water was added dropwise till solution became turbid. The mixture was hold at 5° C. for 10 hrs. Formed crystals were filtered, washed with small amount of cold ether and recrystallized from ethanol. Yield 23.4% as yellow crystals. M.p. 218-219° C. .sup.1H NMR (400 MHz, CDCl.sub.3): δ 1.46 (s, 6H, 2×6-CH.sub.3), 2.13 (d, J=11.6 Hz, 1H, 14-Ha), 2.21 (dd, J=11.6 Hz, J=4.0 Hz, 1H, 14-H.sub.b), 3.78 (s, 3H, 8-OCH.sub.3), 3.82 (t, J=4.0 Hz, 1H, 13-H), 3.93-3.97 (m, 2H, ½CH.sub.2-Ph, 12-H), 4.51 (dd, J=14.8 Hz, J=8.0 Hz, 1H, ½CH.sub.2-Ph), 6.46 (d, J=9.2 Hz, 1H, 4-H), 6.68-6.70 (m, 2H, Ar—H), 6.73-6.75 (m, 2H, Ar—H), 6.79 (d, J=8.8 Hz, 1H, Ar—H), 7.10-7.16 (m, 3H, Ar—H), 7.28-7.31 (m, 1H, NH), 7.93 (d, J=2.8 Hz, 1H, 1-H), 7.97 (dd, J=9.2 Hz, J=2.8 Hz, 1H, 3-H). .sup.13C NMR (100 MHz, CDCl.sub.3): δ 23.0, 26.6, 33.0, 42.1, 42.8, 45.4, 55.9, 78.3, 109.6, 111.1, 111.3, 113.0, 116.3, 124.6, 125.3, 125.5, 127.4 (2×C), 127.5, 128.5 (2×C), 137.7, 139.8, 141.3, 142.4, 156.0, 158.2, 169.5 (C═O). IR (KBr), ν (cm.sup.−1): 3377 (N—H), 3029, 2975, 1676 (C═O), 1517, 1496, 1340, 1262, 1086, 909.

[0055] Photochromic properties of target compounds 6a,b and 7 were determined from solutions in acetonitrile (10.sup.−5 M/L). Steady state UV-Vis absorption spectra were recorded on scanning spectrometer (Shimadzu UV-3101PC). Flash photolysis experiments were performed with Nd:YAG laser 3-rd harmonic radiation (EKSPLA NL30, pulse energy 3 mJ per impulse, λ=355 nm, pulse duration 5 ns). Number of pulses was determinated counting pulses, while maximum in the light absorption spectrum of opened form reached 0.8 of initial absorption maximum. A solution of benzophenone (0.5 OD at 355 nm) in MeCN, optically adjusted for wavelength of excitation, was used to measure quantum yields. Quantum yield of photochromic transition to opened form was evaluated comparing with control solution according to energetic characteristics (the growth of difference absorbance signal vs exciting pulse energy) and molar extinction coefficient.

[0056] Results of the measurements are provided in the Table.

TABLE-US-00001 Absorption maximum in the visible spectrum of Characteristic Number of Quantum opened form, relaxation time, pulses yield, Compound Structural formula λ.sub.max (nm) T (ns) ΔA/ΔA.sub.0 = 0, 8 φ (%) A [00013] 440 22 4000 5, 5 6a [00014] 490 <5 17000 2, 7 6b [00015] 470 <5 7000 3, 6 7 [00016] 490 <5 5000 2, 2

[0057] The data on photochromic properties presented in the Table show that compounds of present invention can be used as molecular photoswitches, in which under UV radiation opening of 3,4-dihydro-2H-pyran ring occurs and coloured form of compound is generated, with subsequent thermal return to initial non-coloured form. The total duration of formation of coloured form and returning back to non-coloured form is less than 5 ns. The process is repeatable many times. Compounds of the present invention are characterized with high photostability without noticable degradation while operating more than 5000 cycles.

[0058] Compounds of the present invention are less sensitive to alkaline medium, than earlier mentioned compound A. If to a solution of analogue A in acetonitrile we will drop sodium hydroxide solution, immediately hydroxide ion will attack α-C carbon atom, 3,4-dihydropyrane ring will be opened and coloured nitrophenolate forms.

##STR00017##

[0059] Meanwhile spectra provided in FIG. 1 show that after treatment of compound 6a with sodium hydroxide, 3,4-dihydropyrane cycle remains stable and coloured 4-nitrophenolate anion does not form. Compound 6b (FIG. 2) is more sensitive to alkaline medium, but not so sensitive like compound A. Kinetic UV-Vis spectra of compound 6b are provided in FIG. 2.

[0060] In general, the present invention has the following main advantages comparing with the known state of the art:

[0061] 1. The total duration of coloured form formation and returning back to the initial non-coloured state of cis- and trans-methanobenz[f][1,3]oxazepino[3,2-a]indoles of present invention is significantly shorter than in indolino spiropyrans or 1′,3,3′,4-tetrahydrospiro[chromen-2,2′-indoles].

[0062] 2. cis-Methanobenz[f][1,3]oxazepino[3,2-a]indoles are characterized with pecular resistance to changes of medium, and coloured form appears only by action of UV radiation. Alkalies do not open [1,3]benzoxazine ring easily and do not generate coloured 4-nitrophenol fragment.

[0063] 3. Compounds of the invention are characterized with higher resistance to photodestruction than 1′,3,3′,4-tetrahydrospiro[chromen-2,2′-indoles] and withstand more than 5000 opening-closing cycles.

[0064] 4. These compounds are non-sensitive to the oxygen in the air and can be used in environment from which oxygen is not removed.